Navigation Links
Reportlinker Adds Gilead Sciences Inc.: PharmaVitae Profile
Date:10/6/2009

armaceutical sales by geographic region ($m), 2008-14 48

Table 13: Gilead launch portfolio overview ($m), 2008-14 50

Table 14: Gilead core portfolio overview ($m), 2008-14 51

Table 15: Gilead expiry portfolio overview ($m), 2008-14 52

Table 16: Gilead prescription pharmaceutical sales by molecule type ($m), 2008-14 55

Table 17: Gilead prescription pharmaceutical sales by source ($m), 2008-14 57

Table 18: Total Gilead sales by business unit ($m), 2002-08 60

Table 19: Gilead operating revenue/cost analysis ($m), 2002-08 62

Table 20: Gilead operating cost ratio analysis (% of total revenues), 2002-08 63

Table 21: Gilead operating cost ratio analysis (% of total revenues), 2008-14 64

Table 22: Gilead operating revenue/cost analysis ($m), 2008-14 65

Table 23: Key products overview 68

Table 24: Atripla: overview 69

Table 25: Atripla: sales forecast ($m), 2008-14 70

Table 26: Truvada: overview 72

Table 27: Truvada: sales forecast ($m), 2008-14 73

Table 28: Viread: overview 75

Table 29: Viread: sales forecast ($m), 2008-14 76

Table 30: Truvada + rilpivirine: overview 78

Table 31: Truvada + rilpivirine: sales forecast ($m), 2008-14 79

Table 32: Letairis: overview 80

Table 33: Letairis: sales forecast ($m), 2008-14 81

Table 34: Gilead Sciences R&D pipeline (Phase I-registration) 83

TABLE OF FIGURES

Figure 1: The PharmaVitae Explorer 3

Figure 2: Gilead prescription pharmaceutical performance, sales ($m) and growth rate (%), 2002-14 6

Figure 3: Gilead's financial performance ($m), 2002-14 7

Figure 4: Sales of the leading HIV therapy players, 2002-14 ($m) 12

Figure 5: Gilead prescription pharmaceutical sales by source, and therapy area ($m), 2002-14 14

Figure 6:
'/>"/>

SOURCE Reportlinker
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Reportlinker Adds US Disposable Medical Supplies Market Report
2. Tibotec Pharmaceuticals Announces Agreement to Develop and Commercialize a New Fixed-Dose Combination of TMC278 and Truvada(R) With Gilead Sciences
3. U.S. Patent Office Rejects Key HIV/AIDS Drug Patents at PUBPAT Request: Government Finds Prior Art Submitted By PUBPAT Invalidates All of Gilead Sciences Claims
4. Bristol-Myers Squibb and Gilead Sciences Expand Their Alliance to Include Commercialization of ATRIPLA(R) (efavirenz 600 mg/emtricitabine 200 mg/tenofovir disoproxil fumarate 300 mg) in Europe
5. PARIs eFlow Included in Gileads NDA Submission for Aztreonam Lysine for Inhalation
6. Merck/Gilead Once-A-Day AIDS Pill Not Available in Most Places - AHF Urges Speed-Up of Registrations
7. New Momentum Teams With Oracle to Help Reduce Counterfeiting in the Life Sciences Industry
8. Sangamo BioSciences Announces Research Collaboration With UCLA in Human Stem Cells Selected to Receive Clinical Research Award
9. Sangamo BioSciences Announces Plans to Initiate a Second Clinical Trial of CCR5-ZFP Therapeutic to Treat HIV/AIDS
10. Signum Biosciences Awarded Phase II SBIR Grant by the NIH for the Treatment of Rosacea
11. Life Sciences Company Opens Clinical Trial Bridge to India
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/15/2009)... Dec. 15 Rib-X Pharmaceuticals, Inc., a ... of novel drugs for the treatment of serious ... a collaborative research agreement with Massachusetts General Hospital ... for the collaboration, Dr. David Hooper of MGH ... established animal model to determine resistance development and ...
(Date:12/15/2009)... Dec. 15 Decision Resources, one of ... pharmaceutical and healthcare issues, finds that an overall ... for three-quarters of surveyed European oncologists in their ... Avastin for the treatment of breast cancer. ,, ... report entitled European Trends in Targeted Therapies ...
(Date:12/15/2009)... Inc., developer and marketer of the VerifyNow® System, ... measuring an individual,s response to multiple antiplatelet agents, ... number of international and U.S. distribution agreements, as ... capital financing that will take the company into ... its commitment to creating a powerful, worldwide distribution ...
Breaking Medicine Technology:Rib-X Pharmaceuticals Enters into Collaborative Agreement on Delafloxacin with Massachusetts General Hospital 2Rib-X Pharmaceuticals Enters into Collaborative Agreement on Delafloxacin with Massachusetts General Hospital 3For Breast Cancer Treatment, an Agent That Can Achieve an Overall Survival Benefit Would Pose the Greatest Challenge to Avastin's Dominance in Europe 2For Breast Cancer Treatment, an Agent That Can Achieve an Overall Survival Benefit Would Pose the Greatest Challenge to Avastin's Dominance in Europe 3Accumetrics Closes 2009 with Positive Outlook 2Accumetrics Closes 2009 with Positive Outlook 3A Public Option Means a Patient Option 54644 1Mothers Immune System May Block Fetal Treatments for Blood Diseases 54639 1Mothers Immune System May Block Fetal Treatments for Blood Diseases 54639 2Mothers Immune System May Block Fetal Treatments for Blood Diseases 54639 3Mothers Immune System May Block Fetal Treatments for Blood Diseases 54639 4Nucleix Researchers Discover DNA Evidence May Easily be Falsified 3A Company Develops New Detection Technology for Preventing Biological Identity The 13594 1Nucleix Researchers Discover DNA Evidence May Easily be Falsified 3A Company Develops New Detection Technology for Preventing Biological Identity The 13594 2Nucleix Researchers Discover DNA Evidence May Easily be Falsified 3A Company Develops New Detection Technology for Preventing Biological Identity The 13594 3Nucleix Researchers Discover DNA Evidence May Easily be Falsified 3A Company Develops New Detection Technology for Preventing Biological Identity The 13594 4
... Change Reported Unlike What Is Commonly Seen In,Insulin ... Nordisk today announced,results of a new study that ... (insulin detemir [rDNA origin],injection). Patients with Type ... of Levemir® and achieve improvements in blood,sugar, comparable ...
... data from an,investigational study released at the ... showed that initial,combination therapy with Januvia(TM) (sitagliptin) ... beta cell,function in patients with type 2 ... ability of the body to produce,insulin, a ...
Other Medicine Technology:New Study Shows A1c Reduced Safely By Patients With Type 2 Diabetes,Using Self-Adjusted Dosing Starting With Once-Daily Insulin,Treatment Levemir 2New Study Shows A1c Reduced Safely By Patients With Type 2 Diabetes,Using Self-Adjusted Dosing Starting With Once-Daily Insulin,Treatment Levemir 3New Study Shows A1c Reduced Safely By Patients With Type 2 Diabetes,Using Self-Adjusted Dosing Starting With Once-Daily Insulin,Treatment Levemir 4New Study Shows A1c Reduced Safely By Patients With Type 2 Diabetes,Using Self-Adjusted Dosing Starting With Once-Daily Insulin,Treatment Levemir 5An Investigational Study Released at ADA Showed that Initial,Combination Therapy with Januvia (sitagliptin) and Metformin Led to,Improvement in Markers of Beta Cell Function in Patients with Type,2 Diabetes 2An Investigational Study Released at ADA Showed that Initial,Combination Therapy with Januvia (sitagliptin) and Metformin Led to,Improvement in Markers of Beta Cell Function in Patients with Type,2 Diabetes 3An Investigational Study Released at ADA Showed that Initial,Combination Therapy with Januvia (sitagliptin) and Metformin Led to,Improvement in Markers of Beta Cell Function in Patients with Type,2 Diabetes 4An Investigational Study Released at ADA Showed that Initial,Combination Therapy with Januvia (sitagliptin) and Metformin Led to,Improvement in Markers of Beta Cell Function in Patients with Type,2 Diabetes 5An Investigational Study Released at ADA Showed that Initial,Combination Therapy with Januvia (sitagliptin) and Metformin Led to,Improvement in Markers of Beta Cell Function in Patients with Type,2 Diabetes 6An Investigational Study Released at ADA Showed that Initial,Combination Therapy with Januvia (sitagliptin) and Metformin Led to,Improvement in Markers of Beta Cell Function in Patients with Type,2 Diabetes 7An Investigational Study Released at ADA Showed that Initial,Combination Therapy with Januvia (sitagliptin) and Metformin Led to,Improvement in Markers of Beta Cell Function in Patients with Type,2 Diabetes 8An Investigational Study Released at ADA Showed that Initial,Combination Therapy with Januvia (sitagliptin) and Metformin Led to,Improvement in Markers of Beta Cell Function in Patients with Type,2 Diabetes 9An Investigational Study Released at ADA Showed that Initial,Combination Therapy with Januvia (sitagliptin) and Metformin Led to,Improvement in Markers of Beta Cell Function in Patients with Type,2 Diabetes 10An Investigational Study Released at ADA Showed that Initial,Combination Therapy with Januvia (sitagliptin) and Metformin Led to,Improvement in Markers of Beta Cell Function in Patients with Type,2 Diabetes 11An Investigational Study Released at ADA Showed that Initial,Combination Therapy with Januvia (sitagliptin) and Metformin Led to,Improvement in Markers of Beta Cell Function in Patients with Type,2 Diabetes 12An Investigational Study Released at ADA Showed that Initial,Combination Therapy with Januvia (sitagliptin) and Metformin Led to,Improvement in Markers of Beta Cell Function in Patients with Type,2 Diabetes 13An Investigational Study Released at ADA Showed that Initial,Combination Therapy with Januvia (sitagliptin) and Metformin Led to,Improvement in Markers of Beta Cell Function in Patients with Type,2 Diabetes 14An Investigational Study Released at ADA Showed that Initial,Combination Therapy with Januvia (sitagliptin) and Metformin Led to,Improvement in Markers of Beta Cell Function in Patients with Type,2 Diabetes 15An Investigational Study Released at ADA Showed that Initial,Combination Therapy with Januvia (sitagliptin) and Metformin Led to,Improvement in Markers of Beta Cell Function in Patients with Type,2 Diabetes 16An Investigational Study Released at ADA Showed that Initial,Combination Therapy with Januvia (sitagliptin) and Metformin Led to,Improvement in Markers of Beta Cell Function in Patients with Type,2 Diabetes 17An Investigational Study Released at ADA Showed that Initial,Combination Therapy with Januvia (sitagliptin) and Metformin Led to,Improvement in Markers of Beta Cell Function in Patients with Type,2 Diabetes 18An Investigational Study Released at ADA Showed that Initial,Combination Therapy with Januvia (sitagliptin) and Metformin Led to,Improvement in Markers of Beta Cell Function in Patients with Type,2 Diabetes 19An Investigational Study Released at ADA Showed that Initial,Combination Therapy with Januvia (sitagliptin) and Metformin Led to,Improvement in Markers of Beta Cell Function in Patients with Type,2 Diabetes 20An Investigational Study Released at ADA Showed that Initial,Combination Therapy with Januvia (sitagliptin) and Metformin Led to,Improvement in Markers of Beta Cell Function in Patients with Type,2 Diabetes 21An Investigational Study Released at ADA Showed that Initial,Combination Therapy with Januvia (sitagliptin) and Metformin Led to,Improvement in Markers of Beta Cell Function in Patients with Type,2 Diabetes 22An Investigational Study Released at ADA Showed that Initial,Combination Therapy with Januvia (sitagliptin) and Metformin Led to,Improvement in Markers of Beta Cell Function in Patients with Type,2 Diabetes 23An Investigational Study Released at ADA Showed that Initial,Combination Therapy with Januvia (sitagliptin) and Metformin Led to,Improvement in Markers of Beta Cell Function in Patients with Type,2 Diabetes 24An Investigational Study Released at ADA Showed that Initial,Combination Therapy with Januvia (sitagliptin) and Metformin Led to,Improvement in Markers of Beta Cell Function in Patients with Type,2 Diabetes 25An Investigational Study Released at ADA Showed that Initial,Combination Therapy with Januvia (sitagliptin) and Metformin Led to,Improvement in Markers of Beta Cell Function in Patients with Type,2 Diabetes 26An Investigational Study Released at ADA Showed that Initial,Combination Therapy with Januvia (sitagliptin) and Metformin Led to,Improvement in Markers of Beta Cell Function in Patients with Type,2 Diabetes 27An Investigational Study Released at ADA Showed that Initial,Combination Therapy with Januvia (sitagliptin) and Metformin Led to,Improvement in Markers of Beta Cell Function in Patients with Type,2 Diabetes 28An Investigational Study Released at ADA Showed that Initial,Combination Therapy with Januvia (sitagliptin) and Metformin Led to,Improvement in Markers of Beta Cell Function in Patients with Type,2 Diabetes 29An Investigational Study Released at ADA Showed that Initial,Combination Therapy with Januvia (sitagliptin) and Metformin Led to,Improvement in Markers of Beta Cell Function in Patients with Type,2 Diabetes 30An Investigational Study Released at ADA Showed that Initial,Combination Therapy with Januvia (sitagliptin) and Metformin Led to,Improvement in Markers of Beta Cell Function in Patients with Type,2 Diabetes 31An Investigational Study Released at ADA Showed that Initial,Combination Therapy with Januvia (sitagliptin) and Metformin Led to,Improvement in Markers of Beta Cell Function in Patients with Type,2 Diabetes 32
(Date:12/15/2009)... accurate a surgical method, with fewer complications, analysis finds, ... comes to diagnosing breast cancer, women and their doctors ... less invasive "core needle biopsy" procedure is nearly as ... procedure is, with fewer complications than the surgical version. ... Jan. 5 issue of Annals of Internal Medicine ...
(Date:12/15/2009)... Dec. 15 Mergers and acquisitions are ... their reach globally or complete a product portfolio ... integration of safety programs. ,, A new free, ... Practices in a Hearing Conservation Program: US Airways ... and America West led the newly formed company ...
(Date:12/15/2009)... Aon Consulting, the global human capital consulting ... AON ), today announced Lisa Zeitel has ... with the Health & Benefits Practice and ... ,, (Logo: http://www.newscom.com/cgi-bin/prnh/20041215/CGW049LOGO ) ,, ... under the direction of Aon Consulting,s Pharmacy ...
(Date:12/15/2009)... CLARA, Calif., Dec. 15 Today, ... into Santa Clara County for the first ... Effective immediately, Coastal Healthcare Administrators will be ... by the Physicians Foundation for Medical Care. ... healthcare philosophy, Coastal maintains close working relationships ...
(Date:12/15/2009)... Visits to a gynaecologist or midwife are generally ... but could offer so much more. Women, doctors ... great opportunities for dialogue about sexual health, reveals ... University of Gothenburg, Sweden. , Many young women ... Almost 500 women aged 23-29 answered questions about ...
Breaking Medicine News(10 mins):Health News:Needle Biopsy Works Well in Diagnosing Breast Cancer 2Health News:New White Paper Details Best Practices of an Occupational Hearing Conservation Program: US Airways 2Health News:New White Paper Details Best Practices of an Occupational Hearing Conservation Program: US Airways 3Health News:New White Paper Details Best Practices of an Occupational Hearing Conservation Program: US Airways 4Health News:Aon Consulting Adds Senior Vice President to National Pharmacy Practice 2Health News:Aon Consulting Adds Senior Vice President to National Pharmacy Practice 3Health News:Aon Consulting Adds Senior Vice President to National Pharmacy Practice 4Health News:Coastal Healthcare Administrators Expands Provider Network to Santa Clara County 2Health News:More about sex and relationships needed at gynecological visits 2
... Management Services, Inc. (EMSI) is pleased to announce a ... position in the business segments they serve and to ... markets. Effective April 1, 2009, the company will ... Healthcare Services and Investigative Services.The Insurance Services Division will ...
... Oscar Night Celebrations in HollywoodNAPA, Calif., Feb. 19 ... of premium wines, and a sponsor of the Elton ... for the EJAF gala dinner and Academy Awards Viewing ... the 6th consecutive year, Sterling Vineyards will be the ...
... Analysis is interesting, but doesn,t prove cause and effect, ... Living in neighborhoods packed with fast-food joints could increase ... residing in places where such restaurants are less plentiful, ... to be causal is not known, though, said study ...
... YORK, Feb. 19 Medicsight PLC, a subsidiary ... an industry leader in the development of Computer-Aided ... radiologists in the early detection of disease, today ... effective March 19, 2009. Allan Rowley, currently Chief ...
... Feb. 19 A new analysis from the JUPITER ... in San Diego, California describes details of the stroke ... This data adds to the primary analysis of ... 20mg significantly reduced the risk of stroke by nearly ...
... Hospice Foundation announces the appointment of Brickson Diamond, ... of Trustees. As Board Chair, Diamond will lead ... to advance quality, compassionate end-of-life care for all.Diamond ... Trust Company,s Personal Investment Management Division and a ...
Other Medicine News:Health News:EMSI Realigns Internal Divisions for More Effective Focus on Customers 2Health News:Diageo Chateau & Estate Wines Renews Official Wine Sponsorship of Elton John AIDS Foundation(R) 2Health News:More Fast-Food Joints in Neighborhoods Mean More Strokes 2Health News:Medicsight PLC Restructures Management Team 2Health News:Medicsight PLC Restructures Management Team 3Health News:CRESTOR Cuts Risk of Stroke by Nearly Half in JUPITER Study 2Health News:CRESTOR Cuts Risk of Stroke by Nearly Half in JUPITER Study 3Health News:CRESTOR Cuts Risk of Stroke by Nearly Half in JUPITER Study 4Health News:Brickson Diamond Appointed Board Chair of National Hospice Foundation 2
Solid 15 mm blades with 8 mm narrowed portion. Screw-controlled locking mechanism with stabilizing disk. Dull finish....
Pediatric model. Spring-controlled spread of blades with locking mechanism. Dull finish. Blades: 11 mm....
Adult model. Spring-controlled spread of blades with locking mechanism. Dull finish. Blades: 14 mm....
Solid 14 mm free-swinging blades, suture posts, and stabilizing disk. Dull finish....
Medicine Products: